HDAC1 and HDAC8 inhibition
Biochemical assay · A2780-derived immunoprecipitated HDAC1 complexes and recombinant human HDAC8 [1]
Assay-specific enzyme inhibition; these IC50 values are not cellular treatment concentrations.
| Endpoint | Reported result | Reference |
|---|---|---|
| Inhibition of HDAC1-complex deacetylase activity | IC50 3.31±0.78 nM | [1] |
| Inhibition of recombinant human HDAC8 activity | IC50 23±17 nM | [1] |
Literature-Reported Treatment Conditions
- Treatment concentration
- Increasing inhibitor concentrations; exact range not specified in the selected assay methods.
- Exposure duration
- HDAC1: 10-min inhibitor preincubation, followed by 45-min reaction.
- Method
- Biochemical enzyme activity assays; panobinostat, vorinostat, MS-275 and TSA comparator values are presented in Table 1.
- Vehicle
- DMSO stocks; final assay DMSO fraction not specified.
- Reported limits
- HDAC8 incubation duration and explicit zero-inhibitor well composition are not specified in the retrieved assay description.
Methods and source locations
Compound reported in the paper: R306465; Compound label in the paper: JNJ-16241199
Evidence concerns the reported research material; no Adooq lot equivalence is established.
Table 1 and footnote; Materials and methods: Compounds and Histone deacetylase activity assays; Figure 1
Inhibition of HDAC1-complex deacetylase activity: Radiolabeled acetyl-H4 peptide substrate; mean±s.d., three independent experiments on one lysate. — Table 1, R306465 row, HDAC1-IP Ac-H4 column; Histone deacetylase activity assays
Inhibition of recombinant human HDAC8 activity: Commercial HDAC8 colorimetric/fluorimetric assay; Table 1 describes mean±s.d. for three independent experiments. — Table 1, R306465 row, HDAC8 column and footnote